Faculty Profile
Address:
622 West 168th Street
Room 1276
New York, NY 10032
Phone: 212-305-3171
Fax: 212-305-6486
| Education and Training | ||
| M.D. | 1979 | Thomas Jefferson Univeristy |
| Resident | 1980-82 | Temple University Hospital, Phil, PA |
| Fellow, Endocrinology | 1982-84 | University of Chicago |
| Fellow, Immunology | 1984-86 | University of Chicago |
Affiliations
Department
of Medicine
Naomi
Berrie Diabetes Center
Stem Cell Consortium
| Kevan
Herold, M.D. Professor |
Research
Summary
Dr. Kevan Herold is an Endocrinologist with a special interest in autoimmune
diseases and diabetes. He sees adolescent and adult patients with all
forms of diabetes and other metabolic disorders. Dr. Herold is conducting
research on immunotherapy for treatment of Type 1 diabetes and is the
Medical Director of the Islet Transplantation program at Columbia University
Medical Center.
Dr. Herold’s laboratory work involves studies of induction of immunologic tolerance to autoimmunity. His current clinical trials are listed below.
Service
Activities
2004 – Permanent member, Immunologic Sciences Study Secton, NIH
Selected Publications
1. Steele C, Cavaghan M, Hagopian WA, Gitelman S, Masharanai U, Rother K, Donaldson D, Harlan D, Bluestone J, and Herold KC. Insulin secretion in Type 1 diabetes mellitus. Diabetes 53:426-433, 2004.
2. Taylor L and Herold KC. New treatments in type 1diabetes: Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: Induction of immune regulation? Immunologic Research 28:141-150, 2003.
3. Glandt M, Hagopian W, and Herold KC. Anti-CD3 treatment for Type 1 diabetes mellitus. Reviews in Endocrine and Metabolic Disorders 4:361-8, 2003.
4. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest. 2003 Feb;111(3):409-18.
5. Herold
KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson
D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3
monoclonal antibody in new-onset type 1 diabetes mellitus. N
Engl J Med. 2002 May 30;346(22):1692-8.
Current Clinical Trials
1.
Type 1 Diabetes TrialNet: Clin Ctr at Columbia University
This application is to establish a Clinical Center of TrialNet at the
Naomi Berrie Diabetes Center at Columbia University. At this Center,
trial for prevention and treatment of Type 1 diabetes are conducted.
National Institute of Diabetes and Digestive and Kidney Diseases
9/30/2001-6/30/2008
2.
Phase I/II Trial and Phase II trial of HOKT3(1(ALA-ALA)) in Type
1 Diabetes
This application is for trials of anti-CD3 mAb, hOKT3gamma1 (Ala-Ala)
for treatment of new onset (T1DM). The support for these studies is from
the Immune Tolerance Network and NIDDK.
Immune tolerance Network, NIAID, National Institute of Diabetes and Digestive
and Kidney Diseases
6/15/2000-3/31/2007
3.
Islet cell resource Center at Columbia University:
Dr. Herold is the Co-principal investigator for an Islet Cell Resource
laboratory at Columbia University. This Center sponsors trials involving
islet cell transplant. Currently a trial of islet transplantation in
patients with Type 1 diabetes with a stable kidney transplant is ongoing.
National Center for Research Resources
Honors and Awards
| 1975 | President's Freshman Achievement Award |
| 1977 | Graduated Summa Cum Laude |
| 1977 | Measey Scholarship |
| 1978 | Who's Who Among Students in American Colleges and Universities |
| 1978 | Alpha Omega Alpha Honor Medical Society |
| 1979 | Graduated Cum Laude |
| 1983, 1985 and 1988 | Young Investigators' Research Award, ADA, Northern Illinois Affiliate |
| 1988-1990 | Career Development Award, Juvenile Diabetes Foundation International |
| 1990 | Clinical Investigator Award, NIDDK, National Institutes of Health |
Keywords
diabetes mellitus therapy, human therapy evaluation, immunotherapy, insulin dependent diabetes mellitus, monoclonal antibody, T lymphocyte, clinical trial phase I, leukocyte activation /transformation, clinical research, human subject